Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PharmAbcine, Inc.
Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
- Large Molecule
- Other Names / Subsidiaries
- PharmAbcine Australia Pty. Ltd.
- Wincal Biopharm, Inc.